F071 Skin-environmental Interface: Dermatologic Challenges of Our Changing Climate and Environment
DESCRIPTION
Climate change is an existential threat. With greater intensity and frequency of extreme weather events, serious health consequences are occurring now and threaten future generations. Dermatologists are uniquely positioned to advocate for public health, educate patients on the cutaneous manifestations of climate change, and create innovative solutions for mitigation. This session will highlight how climate change and pollution influence infectious, inflammatory, and autoimmune skin diseases with attention to disproportionately affected populations. This forum will provide learners with knowledge of key health impacts, tools to build sustainable practices, and opportunities for advocacy and engagement.
LEARNING OBJECTIVES
Examine the scientific consensus on climate change and its impacts on cutaneous disease and the practice of dermatology.
Define the impacts of global warming, climate change, and pollution on cutaneous disease and recognize the vulnerable populations that are disproportionately affected by these
Implement strategies to reduce our professional carbon footprint and identify advocacy opportunities
SCHEDULE
3:30 PM
Overview of the Impacts of Climate of Change in Dermatology
Eva R. Parker, MD, FAAD
3:50 PM
Climate Impacts on Pediatric Skin Disease
Sarah Jane Coates, MD, FAAD
4:04 PM
Impacts of Climate Change and Air Pollution on Chronic Skin Disease
Alexandra P Charrow, MD, FAAD
4:18 PM
Impact of Climate Change in the Global South with a Focus on Pakistan
Aisha Sethi, MD, FAAD
4:32 PM
The Environmental Impact of Biologic Therapy
Tina Bhutani, MD, FAAD
4:46 PM
Mohs Surgical Waste
Zachary A. Zinn, MD, FAAD
5:00 PM
Where we’ve been and where we’re going in dermatology
Misha Rosenbach, MD, FAAD
5:15 PM
Q&A
DIRECTOR
Eva R. Parker, MD, FAAD
SPEAKERS
Tina Bhutani, MD, FAAD
Alexandra P Charrow, MD, FAAD
Sarah Jane Coates, MD, FAAD
Misha Rosenbach, MD, FAAD
Aisha Sethi, MD, FAAD
Zachary A. Zinn, MD, FAAD
DISCLOSURES
Tina Bhutani, MD, FAAD
AbbVie – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Amgen – Investigator(Grants/Research Funding), Speaker(Honoraria); Apogee BioPharm – Advisory Board(Honoraria); Arcutis Biotherapeutics – Speaker(Honoraria); Arcutis, Inc. – Advisory Board(Fees); ASLAN Pharmaceuticals – Data Safety Monitoring Board(Fees), Data Safety Monitoring Board(Honoraria); Boehringer Ingelheim – Advisory Board(Fees); Bristol Myers Squibb – Speaker(Honoraria); Bristol-Myers Squibb – Advisory Board(Fees); Castle Biosciences – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Celgene – Investigator(Grants/Research Funding); Clementia Pharmaceuticals – Investigator(Grants/Research Funding); CoreEvitas, LLC – Investigator(Grants/Research Funding); Dermatology Foundation – Speaker(Honoraria); Dermavant Sciences – Investigator(Grants/Research Funding); Dermavant Sciences, Inc. – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Eli Lilly – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Eli Lilly and Company – Advisory Board(Fees); FIDE – Consultant(Fees); Galderma – Advisory Board(Honoraria), Speaker(Honoraria); Happify – Consultant(Fees); Incyte – Advisory Board(Honoraria); Janssen Biotech – Speaker(Honoraria); Janssen Pharmaceuticals, Inc – Advisory Board(Fees); Janssen Research & Development, LLC – Investigator(Grants/Research Funding); LearnSkin – Speaker(Honoraria); Leo Pharma – Speaker(Honoraria); LEO Pharma, US – Advisory Board(Fees); Mindera – Investigator(Grants/Research Funding), Speaker(Honoraria); National Psoriasis Foundation – Speaker(Honoraria); Novartis – Advisory Board(Fees), Investigator(Grants/Research Funding); Ortho Dermatologics – Speaker(Honoraria); Oruka Therapeutics – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker/Faculty Education(Honoraria); Regeneron Pharmaceuticals, Inc. – Investigator(Grants/Research Funding); Sanofi – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Honoraria); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria); Taxa – Consultant (1099 relationship)(Stock); UCB – Advisory Board(Fees), Speaker(Honoraria);
Alexandra P Charrow, MD, FAAD
Avalo – Consultant (1099 relationship)(Fees); Dermatology Foundation – Investigator(Grants/Research Funding); Hidradenitis Suppurativa Foundation – Board of Directors(No Compensation Received), Investigator(Grants/Research Funding); Incyte Corporation – Advisory Board(Fees), Investigator(No Compensation Received); Insmed – Investigator(No Compensation Received); Insmed Incorporated – Investigator(No Compensation Received); Novartis Pharmaceuticals Corp. – Advisory Board(Fees); Q32 Bio Inc. – Consultant (1099 relationship)(No Compensation Received); Sonoma Biotherapeutics – Investigator(No Compensation Received); UCB Pharma – Advisory Board(Honoraria); Wedbush Securities – Consultant (1099 relationship)(Honoraria);
Sarah Jane Coates, MD, FAAD
No financial relationships exist with ineligible companies.
Eva R. Parker, MD, FAAD
L'Oreal – Advisory Board(Honoraria);
Misha Rosenbach, MD, FAAD
Google Ventures – Consultant (1099 relationship)(Honoraria); J&J Innovative Medicine – Consultant(Honoraria); Merck & Co., Inc – Consultant(Honoraria); OpenEvidence – Advisory Board(Other Financial Benefit); Priovant Therapeutics – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding);
Aisha Sethi, MD, FAAD
No financial relationships exist with ineligible companies.
Zachary A. Zinn, MD, FAAD
No financial relationships exist with ineligible companies.